Stockreport

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor [Yahoo! Finance]

Skye Bioscience, Inc.  (SKYE) 
PDF unlocking new therapeutic pathways for metabolic health, today announced that it has achieved more than 50% of targeted patient enrollment for its CBeyond™ Phase 2 clini [Read more]